Summary of findings 5. Mesalazine versus mesalazine + cholestyramine for treating collagenous colitis.
| Mesalazine vs. mesalazine + cholestyramine for treating collagenous colitis | ||||||
| Patient or population: Patients with collagenous colitis Setting: Outpatient Intervention: Mesalazine Comparison: Mesalazine + cholestyramine | ||||||
| Outcomes | Anticipated absolute effects* (95% CI) | Relative effect (95% CI) | № of participants (studies) | Quality of the evidence (GRADE) | Comments | |
| Risk with mesalazine + cholestyramine | Risk with Mesalazine | |||||
| Clinical response | 167 per 10001 | 123 per 1000 (83 to 180) | RR 0.74 (0.50 to 1.08) | 23 (1 RCT) | ⊕⊝⊝⊝ very low2,3 | |
| Adverse events | 0 per 10001 | 0 per 1000 (0 to 0) | RR 0.22 (0.01 to 4.07) | 23 (1 RCT) | ⊕⊝⊝⊝ very low2,4 | |
| *The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio; OR: Odds ratio; | ||||||
| GRADE Working Group grades of evidence High quality: We are very confident that the true effect lies close to that of the estimate of the effect Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect | ||||||
1 Control group risk comes from control arm of the included study. 2 Downgraded one level due to high risk of bias for blinding. 3 Downgraded two levels due to very sparse data (20 events). 4 Downgraded two levels due to very sparse data and wide confidence interval (2 events).